FDA Drug Information Updates

1-7 of 7

The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
FDA Drug Information Updates
The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA Drug Information Updates
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA’s Role in Foreign Drug Manufacturing
FDA’s Role in Foreign Drug Manufacturing
FDA Drug Information Updates
FDA’s Role in Foreign Drug Manufacturing
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA Drug Information Updates
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Drug Information Updates
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Drug Information Updates
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
FDA Drug Information Updates
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard

1-7 of 7

Title